Medtronic in vascular puncture haemostasis deal with Scion
This article was originally published in Clinica
Executive Summary
Medtronic is to have exclusive distribution rights to Scion Cardio-Vascular's Clo-Sur PAD, used for the rapid control of bleeding from vascular access sites, and has made a minority equity in investment in the Miami, Florida-based company. Under the deal with Medtronic, use of the noninvasive device is limited to the control of bleeding following catheter removal associated with a catheterisation procedure, such as stenting, and other minimally invasive procedures.